Trastuzumab deruxtecan granted orphan drug designation in the US for the treatment of gastric cancer

In the Phase II DESTINY-Gastric01 trial, trastuzumab deruxtecan was associated with a higher objective response rate (primary endpoint) vs standard chemotherapy (irinotecan or paclitaxel monotherapy) in patients with HER2-positive metastatic gastric or gastroesophageal cancer.

SPS commentary:

Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 antibody (trastuzumab) and a DNA topoisomerase I inhibitor, a DX 8951 derivative. The HER2 antibody is attached to the topoisomerase I inhibitor by a tetrapeptide linker.

The results of the DESTINY-Gastric01 trial will be presented at the 2020 American Society of Clinical Oncology (ASCO20) Virtual Scientific Program.


Biospace Inc.